Kiniksa Pharmaceuticals International, plc (KNSA) stock
KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30481% above fair value
$93.89+0.36 (+0.38%)
Close on Nov 20, 2026Market cap $14.76BP/E 72.2Yield –
Kiniksa Pharmaceuticals International free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Kiniksa Pharmaceuticals International's free cash flow for the twelve months ending Sep 30, 2026 was $197.20M, up 93.8% year over year. For fiscal 2025 it was $136.42M, up 436.8% from the year before. The highest annual figure on record is $136.42M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $136.42M | +436.8% |
| FY2024 | Dec 31, 2024 | $25.41M | +92.9% |
| FY2023 | Dec 31, 2023 | $13.17M | +131.0% |
| FY2022 | Dec 31, 2022 | $5.70M | – |
| FY2021 | Dec 31, 2021 | -$126.71M | – |
| FY2020 | Dec 31, 2020 | -$136.82M | – |
| FY2019 | Dec 31, 2019 | -$161.57M | – |
| FY2018 | Dec 31, 2018 | -$86.30M | – |
| FY2017 | Dec 31, 2017 | -$50.29M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $47.37M | +43.5% |
| Q2 FY2026 | Jun 30, 2026 | $46.53M | +66.6% |
| Q1 FY2026 | Mar 31, 2026 | $50.04M | +125.1% |
| Q4 FY2025 | Dec 31, 2025 | $53.26M | +186.7% |
| Q3 FY2025 | Sep 30, 2025 | $33.01M | – |
| Q2 FY2025 | Jun 30, 2025 | $27.93M | +440.3% |
| Q1 FY2025 | Mar 31, 2025 | $22.23M | +469.4% |
| Q4 FY2024 | Dec 31, 2024 | $18.58M | +335.2% |
| Q3 FY2024 | Sep 30, 2024 | -$2.24M | -113.2% |
| Q2 FY2024 | Jun 30, 2024 | $5.17M | – |
| Q1 FY2024 | Mar 31, 2024 | $3.90M | – |
| Q4 FY2023 | Dec 31, 2023 | $4.27M | – |
| Q3 FY2023 | Sep 30, 2023 | $16.97M | -72.6% |
| Q2 FY2023 | Jun 30, 2023 | -$3.78M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.29M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.54M | – |
| Q3 FY2022 | Sep 30, 2022 | $62.03M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.14M | – |
| Q3 FY2021 | Sep 30, 2021 | -$28.56M | – |
| Q2 FY2021 | Jun 30, 2021 | -$38.84M | – |
| Q1 FY2021 | Mar 31, 2021 | -$40.18M | – |
| Q4 FY2020 | Dec 31, 2020 | -$41.25M | – |
| Q3 FY2020 | Sep 30, 2020 | -$34.33M | – |
| Q2 FY2020 | Jun 30, 2020 | -$29.22M | – |
| Q1 FY2020 | Mar 31, 2020 | -$32.02M | – |
| Q4 FY2019 | Dec 31, 2019 | -$26.17M | – |
| Q3 FY2019 | Sep 30, 2019 | -$29.71M | – |
| Q2 FY2019 | Jun 30, 2019 | -$40.88M | – |
| Q1 FY2019 | Mar 31, 2019 | -$64.82M | – |
| Q4 FY2018 | Dec 31, 2018 | -$31.65M | – |
| Q3 FY2018 | Sep 30, 2018 | -$21.45M | – |
| Q2 FY2018 | Jun 30, 2018 | -$18.15M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.05M | – |
| Q4 FY2017 | Dec 31, 2017 | -$23.38M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.97M | – |
See a number that looks wrong?